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Abstract
NK cells are important antiviral effectors, highly enriched in the liver, with the potential to
regulate immunopathogenesis in persistent viral infections. Here we examined whether
changes in the NK pool are induced when patients with eAg-positive CHB are ‘primed’ with
PegIFNα and importantly, whether these changes are sustained or further modulated long-
term after switching to nucleos(t)ides (sequential NUC therapy), an approach currently
tested in the clinic. Longitudinal sampling of a prospectively recruited cohort of patients with
eAg+CHB showed that the cumulative expansion of CD56bright NK cells driven by 48-weeks
of PegIFNα was maintained at higher than baseline levels throughout the subsequent 9
months of sequential NUCs. Unexpectedly, PegIFNα-expanded NK cells showed further
augmentation in their expression of the activating NK cell receptors NKp30 and NKp46 dur-
ing sequential NUCs. The expansion in proliferating, functional NK cells was more pro-
nounced following sequential NUCs than in comparison cohorts of patients treated with de
novo NUCs or PegIFNα only. Reduction in circulating HBsAg concentrations, a key goal in
the path towards functional cure of CHB, was only achieved in those patients with enhance-
ment of NK cell IFNγ and cytotoxicity but decrease in their expression of the death ligand
TRAIL. In summary, we conclude that PegIFNα priming can expand a population of func-
tional NK cells with an altered responsiveness to subsequent antiviral suppression by
NUCs. Patients on sequential NUCs with a distinct NK cell profile show a decline in HBsAg,
providing mechanistic insights for the further optimisation of treatment strategies to achieve
sustained responses in CHB.
Author Summary
Current therapies for CHB are limited in achieving HBsAg decline and loss leading to a
cure. Although PegIFNαmay be used, the majority of patients progress to NUC therapy
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due to treatment failure. PegIFNα and NUCs used in isolation act differentially on the
immune response; PegIFNα induces NK cell activation and NUC therapy may partially
restore T cell function. Data, however, are limited on the immune effects when these thera-
pies are used in sequence or in combination. Here, we analysed the immune effects of
PegIFNα followed by sequential NUC therapy and show this treatment strategy maintains
the cumulative expansion of antiviral CD56bright NK cells, following PegIFNα-priming.
HBsAg reduction was greater in patients treated with sequential NUCs when compared
with de novo NUCs, highlighting the potential benefit of PegIFNα-priming. Such sus-
tained boosting of NK cells on sequential NUCs following PegIFNα-priming has not pre-
viously been described, raising the potential of ‘long-lived’NK cell populations in keeping
with their emerging adaptive features. These findings provide a mechanistic and immuno-
logical rationale to explore this treatment strategy for CHB whilst awaiting the emergence
of new therapies in the field.
Introduction
Chronic Hepatitis B (CHB) related cirrhosis and hepatocellular carcinoma (HCC) account for
approximately 600,000 deaths per year [1]. Current treatments for Hepatitis B virus (HBV)
include Pegylated Interferon-Alpha (PegIFNα) and nuleos(t)ide analogues (NUCs). Although
PegIFNα provides higher rates of off-treatment HBsAg loss, the gold standard treatment end-
point, [2,3] this is observed in a small proportion of patients. Alternatively, NUCs require life-
long administration to maintain long-term viral suppression and HBsAg loss as a treatment
endpoint is sub-optimal [4–6]. These poor treatment outcomes highlight the limitations of cur-
rent licensed therapies used in isolation. This is the impetus for the exploration of combination
or sequential therapy strategies to improve treatment endpoints, [7,8] and importantly provide
an immunological and mechanistic rationale to guide future therapeutic strategies.
The hallmark of CHB is a dysfunctional immune response; the CD8 T cell repertoire dis-
plays an exhausted phenotype, [9,10] and similarly the antiviral potential of NK cells is also
impaired [11]. NK cells are important innate effector cells making up a significant proportion
of the intrahepatic infiltrate. We have previously demonstrated that the immunoregulatory
CD56bright NK cell subset is highly enriched in the HBV-infected liver, expressing TNF-related
apoptosis-inducing ligand (TRAIL) [12]. Their ability to produce cytokines (IFNγ) allowing
non-cytolytic clearance of HBV-infected hepatocytes has also been shown to be impaired in
CHB [11]. IFNα potently activates NK cells and we recently demonstrated that PegIFNα ther-
apy in eAg negative disease led to a dramatic expansion of activated CD56bright NK cells with
enhanced antiviral potential, though this effect reduced on treatment cessation [13]. Notably
NUC treated eAg negative patients did not show similar NK cell boosting [11] but conversely
demonstrated partial restoration of HBV-specific T cells [14,15].
Here we investigated whether PegIFNα was able to mediate a similarly potent expansion of
functional NK cells in eAg positive CHB as noted in eAg negative disease, and whether any
such boosting could be maintained in patients progressing to sequential NUC therapy follow-
ing PegIFNα. Longitudinal on-treatment NK cell responses were analysed throughout the
course of PegIFNα+/- sequential NUCs, and correlated with clinical parameters of treatment
response. We report for the first time that functional NK cell responses are restored, upon in
vivo administration of PegIFNα, in eAg positive CHB and importantly these effects are pre-
served on sequential NUCs, with an associated decline in quantitative HBsAg exceeding that
seen with either de novo NUC or PegIFNα therapy alone [16]. Insights into this mechanism of
NK Cell Responsiveness & HBV Therapy
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innate boosting in patients receiving sequential NUCs provides further scientific rationale to
support re-evaluation of future treatment strategies.
Results
Expanded CD56bright NK cells are maintained on sequential NUC
therapy
We analysed NK cell subsets in patients, pre, during and following the cessation of PegIFNα
therapy; 9/18 patients, consecutively studied, progressed to sequential NUC therapy and were
studied longitudinally with 3-monthly sampling until viral suppression was achieved. A further
5 patients were studied cross-sectionally during sequential NUCs (Table 1, S1 Table, Fig 1).
PegIFNα profoundly expanded NK cells in this cohort of patients with eAg positive CHB, as
we had previously reported in eAg negative disease [13]. This expansion was more dramatic
for the CD56bright immunoregulatory subset of NK cells, which we have shown to be
Table 1. Baseline characteristics & clinical features of patients (Cohort 1).
Age Gender Genotype ALT HBV DNA HBsAg Fibrosis Outcome Sequential Therapy
(IU/L) (log10IU/ml) (log10IU/ml) (Ishak)
[32] [99] [7.54] [4.31]
Pt.1 35 M A 132 3.68 3.37 2 Responder*^¶ No
Pt.2 49 M C 68 4.36 4.49 3 Non-responder Yes
Pt.3 32 M C 57 5.74 3.73 3 Non-responder Yes
Pt.4 38 F B 52 8.51 4.50 1 Non-responder Yes
Pt.5 26 M C 62 7.21 3.85 4 Responder* No
Pt.6 29 M C 115 8.34 4.80 1 Non-responder Yes
Pt.7 26 F D 29 9.06 4.47 ND Responder*¶ No
Pt.8 26 F C 60 8.28 3.86 2 Non-responder Yes
Pt.9 32 M C 85 9.16 5.04 1 Non-responder¶ No
Pt.10 37 F B 341 8.11 3.02 1 Responder*¶ No
Pt.11 35 M D 91 6.80 4.53 1 Non-responder Yes
Pt.12 22 M A 187 8.20 4.47 3 Non-responder¶ No
Pt.13 32 M C 51 8.69 4.07 2 Non-responder Yes
Pt.14 31 F E 55 7.30 4.33 1 Non-responder¶ No
Pt.15 38 F B 102 7.96 4.17 ND Non-responder Yes
Pt.16 34 M D 133 8.03 4.24 5 Non-responder Yes
Pt.17 32 F D 40 4.46 4.46 1 Non-responder¶ No
Pt.18 26 F D 63 8.24 4.68 2 Non-responder¶ No
Pt.19§ 55 M A 95 8.37 5.10 ND Non-responder Yes
Pt.20§ 18 M A 86 8.18 4.31 3 Non-responder Yes
Pt.21§ 30 M C 112 7.98 4.54 1 Non-responder Yes
Pt.22§ 40 M A 167 9.25 4.52 ND Non-responder Yes
Pt.23§ 33 M D 99 7.48 4.50 1 Non-responder Yes
- Numbers in brackets under headings; age = median values; ALT, HBV DNA & HBsAg = mean values
- ND: Test not done
- *sustained HBeAg seroconversion & HBV DNA <2000IU/ml (<3.30 logIU/ml) 6-months post cessation of Peg-IFNα
- ^sustained HBsAg loss
- ¶lost to follow-up/refused sequential NUC therapy
- §sampled only at selected time-points on sequential NUC therapy
doi:10.1371/journal.ppat.1005788.t001
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preferentially enriched in the HBV-infected liver; [12] this subset was therefore studied com-
prehensively (Figs 2A, 2B and S1A). PegIFNα resulted in a depletion of total circulating lym-
phocytes; however we confirmed that it induced an increase in both percentage and absolute
numbers of CD56bright NK cells (Fig 2A and 2B). The PegIFNα-induced expansion of
CD56bright NK cells showed a non-significant trend to decrease on sequential NUCs, but nota-
bly, their frequency remained significantly higher than baseline. Conversely the CD56dim sub-
set significantly reduced during PegIFNα therapy and tended to return towards baseline on
sequential NUCs (Fig 2C); we therefore focused this study on the CD56bright NK cell subset.
ALT normalisation and reduction in HBV DNA was noted, along with a decline in HBsAg lev-
els corresponding to the time-point of viral suppression on sequential NUCs (Fig 2D).
The expansion of CD56bright NK cells on PegIFNα could be attributed to their increased
proliferation peaking at 9-months after initiation, as assessed by Ki67 expression, a marker of
the replicative S-phase of the cell cycle (Figs 2E and S1B). CD56bright NK proliferation
remained significantly higher on sequential NUCs than that observed at baseline, whereas their
activation (HLA-DR expression) peaked at 9 months of PegIFNα and was not maintained on
sequential NUCs (Fig 2F). By contrast CD56dim NK cells did not have enhanced proliferation
or HLA-DR expression during PegIFNα or sequential NUCs (S1D and S1E Fig).
Fig 1. Schematic overview of patients studied for immune analysis.Cohort 1 indicates sequential NUC therapy patients
studied; 18 consecutive patients were analysed longitudinally during a 48 week course of PegIFNα therapy (blue dashed
outline), of which 9/18 patients progressed to sequential NUC therapy, following a 6–12 week interval gap (grey shaded box),
and were sampled longitudinally; *indicates 5 further patients analysed undergoing sequential NUC therapy, sampled at time-
point month 0 and 9 only on sequential therapy (total sequential NUC therapy cohort; n = 14) (red dashed outline). Cohort 2;
n = 12 patients analysed at a single time-point at viral suppression on de novo NUC therapy (green dashed outline). Cohort 3;
n = 10 patients treated with PegIFNα therapy for 48 weeks that did not undergo any further treatment (grey dashed outline), and
sampled at 9 months following cessation of PegIFNα. Arrows under time-points indicate sampling time for immune analysis in
each cohort.
doi:10.1371/journal.ppat.1005788.g001
NK Cell Responsiveness & HBV Therapy
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CD56bright NK cells express high levels of C-type lectin and natural
cytotoxicity receptors on sequential NUC therapy
NK cells express a variety of receptors that dictate their activity, [17] hence we analysed their
expression of C-type lectin receptors (NKG2A, NKG2C, NKG2D) and natural cytotoxicity
receptors (NCRs) (NKp30, NKp44, NKp46).
We noted an increase in NKG2D and NKG2A on CD56bright NK cells throughout PegIFNα
therapy, which remained significantly elevated on sequential NUCs (Figs 3A, 3B, S2A and
S2B); no such changes were seen on the CD56dim NK cell subset (S2C and S2D Fig). The
expression of the NKG2C receptor was dissimilar. No significant percentage increase in
NKG2C was observed during PegIFNα therapy, although an increase in the absolute number
of these cells was noted compared to baseline (S2E Fig). Moreover, there was no significant
Fig 2. Impact of PegIFNα and sequential NUC therapy on NK cell numbers, proliferation and activation.Cumulative longitudinal
data demonstrating change in CD56bright NK cells over the course of PegIFNα therapy by (A) percent and absolute cell number
(median ± 95%CI), (n = 18). Change in the number of (B) CD56bright NK cells and (C) CD56dim NK cells (by percent and absolute
number) in 9 paired cross-sectional samples in patients on sequential NUC therapy; showing pre-treatment numbers, last sampling
treatment time-point on PegIFNα therapy and final sampling time-point on sequential NUC therapy. (D) Corresponding overall ALT,
HBV DNA and HBsAg levels (mean + SEM) at the aforementioned sampling time-points. Proportion of CD56bright NK cells expressing
(E) Ki67 and (F) HLA-DR, in 9 paired samples, pre-treatment, on PegIFNα and sequential NUC therapy, with representative FACS
plots at these time-points. Significant changes marked with asterisks, *P<0.05;**P<0.01; ***P<0.001, ns = not significant.
doi:10.1371/journal.ppat.1005788.g002
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change in the expression of NKG2C during sequential NUCs (S2F and S2G Fig); all patients
except for 1 were CMV seropositive so the known influence of CMV on NKG2C could not be
discerned in this cohort. NCRs are involved in the clearance of tumour and virus infected cells
[18]; in keeping with this, we noted more striking changes in their expression. A significant
increase in the expression of NKp30, NKp44 and NKp46 on CD56bright NK cells was seen from
6-months of PegIFNα therapy onwards (Figs 3C and S3A–S3C). Importantly further augmen-
tation of NKp30 expression on CD56bright and CD56dim NK cells was observed on sequential
NUCs, peaking at viral suppression, with an inverse temporal relationship noted between its
expression and HBV DNA (Figs 3C, 3G, 3H and S3D). Upon sequential NUCs, both NKp44
and NKp46 were maintained on CD56bright NK cells at higher levels than baseline, with
Fig 3. Impact of sequential NUC therapy on the expression of NK cell receptors and functional capacity of NK cells. Percent of
CD56bright NK cells expressing (A) NKG2D (B) NKG2A (C) NKp30, (D) TRAIL, (E) CD107 and (F) IFNγ in 9 paired cross-sectional
samples pre-treatment, last sampling treatment time-point on PegIFNα therapy and final sampling time-point on sequential NUC
therapy with representative FACS plots at these time-points. Significant changes marked with asterisks, *P<0.05;**P<0.01;
***P<0.001, ns = not significant. Clinical data showing (G) changes in ALT (IU/L), HBV DNA and HBsAg (log10IU/ml) throughout
treatments. Corresponding cumulative summary data indicating dynamic changes in (H) NCRs (NKp30, NKp44 and NKp46), (I) TRAIL,
CD107 and IFNγ expression throughout treatment, correlating with treatment time-points in (G) (Pre = pre-treatment time-point; 12I =
last PegIFNα therapy time-point; 0N = Sequential NUC initiation time-point; 3N, 6N, 9N = 3, 6 and 9-month sampling time-points on
sequential NUC therapy).
doi:10.1371/journal.ppat.1005788.g003
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expression peaking at 6–9 months, in conjunction with the nadir of HBsAg titre, viral load and
ALT (Fig 3G and 3H), but these effects were not seen on the CD56dim NK cells (S3E and S3F
Fig).
NK cell antiviral function is preserved on sequential NUC therapy
The proportion and absolute number of CD56bright NK cells expressing TRAIL increased sig-
nificantly from 3-months of PegIFNα treatment in eAg positive CHB (in line with previous
findings in eAg negative CHB) [13], peaking at 9-months (Figs 3D and S4A), whereas the abso-
lute number of TRAIL+ CD56dim cells did not increase (S4A Fig). TRAIL+ CD56bright NK cells
showed a non-significant trend to decrease on sequential NUCs, in line with the reduction of
viral load and ALT, but remained significantly higher than pre-treatment levels (Figs 3D and
S4D).
PegIFNα induced a potent increase in NK cell degranulation of CD56bright NK cells by per-
cent and absolute number, evident within 3-months of therapy initiation (Figs 3E and S4B); in
addition an increase in percent but not absolute number of CD107a+ CD56dim cells was seen
(S4B Fig). The ability of CD56bright and CD56dim NK cells to degranulate was maintained on
sequential NUCs, peaking at the 6-month time-point (Figs 3E, 3I and S4E).
The cytokine producing CD56bright NK cell subset shows limited ability to produce IFNγ in
CHB, [11] however patients with eAg positive CHB achieved a striking recovery of the IFNγ
producing capacity of their CD56bright NK cells throughout the course of PegIFNα (Figs 3F
and S4C). IFNγ production was maintained on sequential NUCs to a variable degree, at levels
significantly higher than baseline (Fig 3F). Improvement in clinical parameters (ALT normali-
sation, reduction in HBsAg and HBV DNA levels) on sequential NUCs was associated with sig-
nificantly higher proportion of IFNγ+ CD56bright NK cells at each sequential NUC therapy
time-point when compared to NUC initiation (Fig 3F–3H), effects which were not seen on the
CD56dim NK cell subset (S4C and S4F Fig).
Phenotypic and functional capacity of NK cells is greater on sequential
NUC therapy compared to de novo NUC therapy or PegIFNα therapy
alone
Maintenance of an expanded population of NK cells with altered receptor expression and
enhanced function in patients receiving sequential NUCs was noteworthy, contrasting with
published findings in patients receiving de novo NUC therapy [11]. To confirm this, we com-
pared the immunological changes documented following sequential NUC therapy (Cohort 1)
(S1 Table, Fig 1) with those in virally suppressed patients at a similar time-point on de novo
NUC therapy (Cohort 2) (S2 Table, Fig 1). In addition we compared them to patients treated
with PegIFNα alone who were sampled 9 months post-treatment (Cohort 3), (S3 Table, Fig 1),
to determine if the changes seen on sequential NUCs were merely delayed effects of PegIFNα.
Prior to commencing NUC therapy, patients in cohort 1 and 2 had similar HBV DNA levels,
and no statistically significant difference in HBsAg concentrations (S1 and S2 Tables).
Previous data have shown that CHB patients virally suppressed with de novo NUCs have
reduced levels of circulating CD56bright NK cells, similar to those found in healthy individuals
[11]. Instead, we noted that patients on sequential NUCs had higher frequencies of CD56bright
NK cells, associated with an increase in their proliferative capacity, than those virally sup-
pressed on NUCs alone (Fig 4A). In addition, sequential NUC patients also had a higher fre-
quency of CD56bright NK cells compared with the PegIFNα therapy only cohort (Cohort 3),
although there was no significant difference in their proliferation between these cohorts (Fig
4A).
NK Cell Responsiveness & HBV Therapy
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There was no difference in the expression of HLA-DR (S5A Fig), but we did note a higher
proportion of CD56bright NK cells expressing the early activation marker, CD69, in patients on
sequential NUCs compared to those on de novo NUCs or previous PegIFNα therapy only. In
addition the increase in CD69 expression on PegIFNα treatment was maintained on sequential
NUCs (Fig 4A). Significantly higher levels of NKG2A, NKG2D and NCR expression were
observed in the sequential NUC therapy cohort compared with those on de novo NUCs or the
PegIFNα only cohort (Fig 4B and 4C), but no difference was seen in NKG2C expression
Fig 4. Comparison of NK cells on sequential NUC therapy with de novo NUC therapy & PegIFNα only
therapy. Percentage of CD56bright NK cells and markers in the cohort of patients treated with sequential NUC
therapy (Cohort 1; n = 14, red outline bars), compared with the cohorts of patients treated with nucleos(t)ide
analogues—de novo NUC therapy (Cohort 2; n = 12, green outline bars), without previous PegIFNα
exposure, and with PegIFNα alone with no further therapy for 9 months (Cohort 3; n = 10, grey outline bars).
Sampling time-point is at viral suppression for patients in cohort 1 and 2. The end of treatment (EoT) PegIFNα
sampling time-point for cohort 1, is shown in the blue outline bars for comparison. Markers shown (A)
CD56bright NK cells, Ki67, CD69, (B) NKG2A, NKG2D, (C) NKp30, NKp44, NKp46, (D) TRAIL, CD107, IFNγ.
Results are expressed as mean ± SEM. Significant changes marked with asterisks, *P<0.05;**P<0.01;
***P<0.001, ns = not significant.
doi:10.1371/journal.ppat.1005788.g004
NK Cell Responsiveness & HBV Therapy
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between the cohorts (S5B Fig). Of particular note, the functional potential of CD56bright NK
cells was also increased on sequential NUCs compared to those on de novo NUCs or PegIFNα
only. (Fig 4D).
Evidence of NK cell migration markers seen during sequential NUC
therapy
To further characterise NK cells in the therapy cohorts studied, we analysed their expression of
tissue homing/migration and maturation markers. CD62L and CCR7 are implicated in NK cell
lymph node homing whereas NK cell recruitment to local tissue sites remains less well under-
stood [19]. However chemokine receptors such as CXCR3 [20] and the selectin CD62L [21]
have recently been reported to be important for homing and/or protective roles of NK cells in
the liver. We found that the expression of CD62L was localised to the CD56bright NK subset
and was significantly higher in patients during PegIFNα therapy and upon viral suppression
on sequential NUCs, compared with de novo NUCs and after PegIFN alone, (Fig 5A). We did
not, however, see similar findings with the expression of CCR7 or CXCR6 on this subset (S5C
and S5D Fig). Patients on PegIFNα therapy and sequential NUCs also expressed CXCR3+
CD56bright NK cells at significantly higher levels than those patients virally suppressed on de
novo NUCs or after PegIFNα alone (Fig 5B).
The CD56bright NK cells during sequential NUCs were able to express high levels of CD62L,
CXCR3 and CD69 (Figs 4A, 5A and 5B), but produced low levels of perforin and granzyme,
which localised to the CD56dim NK subset (S5E and S5F Fig). We did not see any change in the
proportion of maturation markers on this NK subset, such that there were no differences in
CD57 or KLRG1+ CD56bright/dim NK cells in the therapy cohorts, (S5G and S5H Fig) but a
Fig 5. Expression of NK cell migration markers on sequential NUC therapy compared with de novo NUC therapy &
PegIFNα only therapy. Percentage of CD56bright NK cells expressing (A) CD62L and (B) CXCR3 in the cohort of patients treated
with sequential NUC therapy (Cohort 1; n = 14, red outline bars), compared with the cohorts of patients treated with nucleos(t)ide
analogues—de novo NUC therapy (Cohort 2; n = 12, green outline bars), without previous PegIFNα exposure, and with PegIFNα
alone with no further therapy for 9 months (Cohort 3; n = 10, grey outline bars). Sampling time-point is at viral suppression for
patients in cohort 1 and 2. The end of treatment (EoT) PegIFNα sampling time-point for cohort 1, is shown in the blue outline bars
for comparison. Representative FACS plots for each corresponding treatment cohort are shown. Results are expressed as
mean ± SEM. Significant changes marked with asterisks, *P<0.05;**P<0.01; ***P<0.001, ns = not significant.
doi:10.1371/journal.ppat.1005788.g005
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modest increase in the CD16+ CD56bright NK cell subsets during PegIFNα and sequential
NUCs compared to the other therapy cohorts (S5I Fig).
Functional NK cell restoration temporally correlates with HBsAg decline
on sequential NUC therapy
Congruent with the enhanced boosting of functional NK cells, patients treated with sequential
NUCs achieved a greater decline in HBsAg than those treated for an equivalent duration with
de novo NUCs (Fig 6A). To confirm this, we compared the decline in HBsAg achieved after
9–12 months of NUCs in a larger cohort of patients with or without prior PegIFNα; again, the
decrease in HBsAg was significantly greater in those on sequential NUCs (Fig 6B).
Marked variability in the maintenance of IFN-induced changes in NK cells in patients on
sequential NUCs was noted (Fig 6). We analysed if NK cell functionality was associated with
differential clinical outcomes in this small cohort. Patients on sequential NUCs (Cohort 1)
were divided according to their HBsAg response; those with any decline in HBsAg from the
time of NUC initiation to viral suppression were classified as ‘HBsAg responders’ and those
without any decline (or even an increase) in HBsAg as ‘HBsAg non-responders’ (Fig 6C). The
overall mean HBsAg decline in the responders (n = 11) was 1.18 logIU/ml, whereas the non-
responders (n = 3) demonstrated a 0.80 logIU/ml increase in HBsAg (Fig 6C).
A striking increase in the capacity of CD56bright NK cells to degranulate and produce IFNγ
was only seen in those considered HBsAg responders. By contrast HBsAg non-responders
showed a significant reduction in NK cell CD107a and IFNγ production, highlighting that
functional restoration of NK cells was seen only in HBsAg responders (Fig 6D and 6E). In con-
trast to other NK cell effector functions, NK cell TRAIL declined in these HBsAg responders
on sequential NUCs (Fig 6F). The association of HBsAg decline with a decrease in TRAIL
expression points to a possible negative impact of TRAIL on immune reconstitution in the set-
ting of sequential NUCs. This is also in keeping with recent studies, where reduced levels of
TRAIL are part of an NK cell phenotype associated with immune control in HBV [15] and sus-
tained virological response following DAA therapy in Hepatitis C virus (HCV) [22,23].
Although the levels of TRAIL remained higher in patients on sequential NUCs following
PegIFNα exposure than in the de novo NUC cohort, we noted significant declines in TRAIL+
CD56bright NK cells in the HBsAg responders, with the greatest decline seen in the patient
(Pt.13) who lost HBsAg (Fig 6F).
Discussion
Here we document for the first time that an expanded population of activated, functional NK
cells induced by a course of Peg-IFNα can be maintained for at least 9 months after switching
to sequential NUCs. This finding is at odds with the traditional view of NK cells as short lived
populations with a rapid turnover and contraction following an acute response [24,25] and is
instead reminiscent of the prolonged expansion of NK cells reported more recently following
homeostatic proliferation in mice [26] and viral infection in humans [27]. Pertinent to this, we
have previously shown that PegIFNα treatment of patients with CHB results in sustained
induction of IL-15, [13] one of the cytokines pivotal to long-term maintenance of NK cells
with ‘recall’ capacity [26,28,29]. In addition a recent study has also demonstrated the role of
type-1 IFN in promoting NK cell expansion during viral infections, by protecting them against
fratricide [30], which may also be relevant in the setting of sequential NUC therapy.
Our data demonstrate that sustained restoration of NK cell responses is associated with an
enhanced decline in HBsAg in a cohort of eAg positive CHB patients exposed to PegIFNα who
subsequently progressed to sequential NUC therapy. These data are the first immunological
NK Cell Responsiveness & HBV Therapy
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Fig 6. Association of change in HBsAg and functional capacity of NK cells. (A) Change in HBsAg titre (log10IU/
ml) from initiation of NUC to viral suppression in the sequential NUC therapy cohort (Cohort 1) compared with de
novo NUC therapy (Cohort 2). (B) Findings in (A) confirmed in a larger cohort of patients; sequential NUC therapy
[n = 28; Baseline (BL): ALT 92 IU/L, HBV DNA 6.65 logIU/ml HBsAg 3.86 logIU/ml], de-novo NUC therapy (n = 30;
BL: ALT 70, HBV DNA 5.79 log IU/ml, HBsAg 3.75 logIU/ml); (p = ns for all BL clinical parameters between the
cohorts). Results are expressed as mean ± SEM. Change in (C) HBsAg titre (log10IU/ml) from initiation of sequential
NUC to viral suppression (9-months of sequential NUC therapy in all patients) in the cohort of sequential therapy
treated patients (unshaded = HBsAg responder; shaded red = HBsAg non-responder), (Patient number
corresponding with number in Table 1 and S1 Table). Change in percentage of (D) CD107+, (E) IFNγ+ and (F)
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characterisation of effects of this treatment sequence, providing a scientific rationale for further
examination of this and other combination or sequential approaches. For example, it maybe
possible to achieve similar immunological effects using shorter courses of PegIFNα according
to current early stopping rules [7]. Previous studies have focused on the impact of these indi-
vidual antiviral therapies on the innate [11,13,15] and adaptive [13–15,31] arms of the immune
response. Recent data show NUC-induced reductions in viral load could prolong the immu-
nostimulatory effects of PegIFNα given in combination, [32] and that NK cells may play a role
in the clearance of HBsAg during these combination therapy strategies [8]. However, no
immunological data exist on the impact of PegIFNα ‘priming’ followed by sequential NUC
therapy for the management of eAg positive CHB. In this eAg positive CHB cohort, PegIFNα
was able to induce a marked expansion of activated CD56bright NK cells with antiviral potential,
as we have previously described for patients with eAg negative CHB [13]. Unexpectedly, these
profound changes in the NK cell compartment were largely maintained for at least 9 months
after switching to sequential NUCs, an effect not seen with de novo NUCs therapy. Thus
PegIFNα appeared to ‘prime’NK cells to sustain long-lasting changes, allowing them to
respond differently to NUCs; in patients not exposed to PegIFNα, NK cells demonstrated
reduced ability to express activating receptors, tissue homing markers/chemokine receptors,
produce IFNγ and degranulate. Interestingly in those patients exposed to PegIFNα only, with-
out further therapy, the functionality of NK cells was not maintained at 9 months post cessa-
tion of PegIFNα. This indicates that the effect seen on sequential NUCs is not exclusively
related to PegIFNα. Furthermore, the differential effects of NUCs on NK cells based on prior
PegIFNα exposure are not explained by differences in baseline viral load or HBsAg levels in
these cohorts. However, sequential NUCs were associated with significantly greater declines in
HBsAg, although no correlation was noted with eAg seroconversion, when compared to de
novo NUCs, which may have been attributable to the NK cell reconstitution and/or have con-
tributed to it. These changes merit further study in a larger cohort.
It is noteworthy nonetheless, that within this small cohort, reductions in HBsAg were tem-
porally associated with increases in NK cell cytotoxicity and IFNγ production, but with reduc-
tions in TRAIL expression, suggesting that the latter may be pathogenic in the setting of
sequential NUCs. We have recently reported that TRAIL-bearing NK cells can delete HBV-
specific T cells and could therefore constrain antiviral T cell immunity [33]. In keeping with
these data, a recent study has shown that NK cell-TRAIL blockade may also lead to recovery of
HBV-specific T cells in eAg negative patients virally suppressed on NUCs [15]. Similarly,
reduced levels of NK cell TRAIL are associated with sustained virological response following
DAA therapy in HCV [22,23]. Although we did not see TRAIL levels return to baseline in the
sequential therapy cohort, we note that there were significant declines in TRAIL+ CD56bright
NK cells in the HBsAg responders, with the greatest decline seen in the one patient who lost
HBsAg.
Not only were IFNα-induced changes in NK cells maintained on sequential NUCs, but the
expression of the activating NCRs, NKp30 and NKp46 were further enhanced on sequential
NUCs, showing an inverse temporal correlation with HBV DNA. Recent data from treated
cohorts in hepatitis C and delta virus have also demonstrated the modulation of these receptors
[22,34–38]. NKp30 has been shown to be pivotal in NK/dendritic cell cross-talk [39,40] and
TRAIL+ CD56bright NK cells from initiation of sequential NUC to viral suppression in each patient in the sequential
therapy cohort with corresponding summary data for HBsAg responders (unshaded) vs. non-responders (shaded
red) for each marker. Significant changes between the groups are marked with asterisks *P<0.05;**P<0.01;
***P<0.001, ns = not significant.
doi:10.1371/journal.ppat.1005788.g006
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the regulation of NK cell IFNγ production; [41] consistent with this, we found that enhanced
IFNγ production reflected NKp30 expression on sequential NUCs. The correlation we
observed between increases in NK cell NKp46 and decline in HBsAg is also in line with data
from the HCV field linking this activating receptor with cytotoxic, [42] antiviral and anti-
fibrotic activity of NK cells [43–45]. In keeping with this, the increased expression of CXCR3+
CD56bright NKs, seen on sequential NUCs, may be implicated in anti-fibrogenesis [20] in HBV
therapies, along with the increased expression of the tissue homing markers, CD62L and
CD69, which may be involved with hepatic NK cell recruitment. Further studies of the ‘on-
treatment’ liver compartment would be of interest to fully elucidate this role.
Despite the limited number of patients studied, these novel data highlight the potential
immunological benefits of PegIFNα-priming as part of a therapeutic strategy. Recent data
from the woodchuck hepatitis model show the induction of a T/NK cell signature in the liver
correlating with treatment outcome [46]. This highlights the potential therapeutic role for
PegIFNα-priming and the resulting modulation of the immune response. Combination or
sequential therapy regimes with PegIFNα and NUCs have been postulated to have the capacity
to exert complementary or synergistic antiviral and immunomodulatory effects. Previous stud-
ies of combination therapies have shown promise in reducing the amount of HBcAg+ hepato-
cytes and cccDNA loads, [47,48] harnessing the different antiviral mechanisms of PegIFNα
and NUCs [7,8,49,50]. Such regimes should likewise take advantage of the ability of PegIFNα
[51] and NUCs [14,15] to reconstitute the innate and adaptive arms of the immune response
respectively [7,13–15]. Our analysis of the virus specific T-cell response in these patient
cohorts, albeit limited, has demonstrated their very low frequency during PegIFNα, with signif-
icant recovery on sequential NUCs (S6 Fig). However, future studies will be required to deter-
mine whether the capacity of NUCs to induce T cell reconstitution is altered by PegIFNα-
priming and its potential effects on NK and T cell interactions [33]. In summary our study sup-
ports the capacity of human NK cells to undergo long-lived changes in the context of in vivo
IFNα exposure followed by NUC therapy and provides a mechanistic rationale for sequential
therapy with PegIFNα followed by NUCs.
Materials and Methods
Ethics statement
Clinical assessment and additional blood sampling were performed during routine hepatitis/
treatment clinics at The Royal London Hospital. Written informed consent was obtained and
the study was approved by the local ethics committee (Barts and The London NHS Trust Ethics
Review Board).
Patient samples/study design
Forty-five eAg positive CHB patients undergoing standard HBV treatment regimes were
recruited for immunological analysis. Baseline HBV serology was measured, including HBV
DNA levels, quantified by real-time PCR (Roche COBAS AmpliPrep/COBAS Taqman HBV
test v2.0-dynamic range 20 to 1.7x108 IU/ml-Roche molecular diagnostics, Pleasanton, CA)
and HBsAg titre (Abbott Architect). Serum was also tested for HBeAg and anti-HBe with a
chemiluminescent microparticle immunoassay (Abbott Architect, Abbott Diagnostics, Abbot
Park, IL) and CMV IgG. HBV genotype was recorded, along with serum transaminases and
Ishak fibrosis stage where liver biopsies were performed.
18 consecutive patients were treated with a 48-week course of Pegylated Interferon-α 2a
(180μg/week-Pegasys) as first-line therapy (Cohort 1). Treatment responses were defined in
accordance with national and international guidelines [2–5] and those considered PegIFNα
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failures/non-responders 6–12 weeks following cessation of PegIFNα (determined by viral
rebound, ALT flare or both), (14/18 patients) were offered Entecavir or Tenofovir; defined as
sequential NUC therapy for the purpose of this study (taken up by nine of these patients).
Detailed longitudinal sampling was carried out on patients from Cohort 1 to characterise tem-
poral immunological changes throughout PegIFNα and sequential NUC therapy. In addition a
further 5 patients, deemed treatment failures, following a 48-week course of PegIFNα, pro-
gressed to sequential NUC therapy, and were also studied, prior to starting NUC and at viral
suppression. (Fig 1, Table 1 and S1 Table). Immune changes after 9 months of sequential
NUCs, in this cohort (n = 14), were compared cross-sectionally with the following control
cohorts sampled at an equivalent time point: Control Cohort 2; 12 patients treated with de
novo NUC therapy (Fig 1, S2 Table). Control Cohort 3; 10 patients treated with PegIFNα for
48 weeks, (responders, n = 4; non-responders, n = 6), sampled 9 months after cessation of
PegIFNα (Fig 1, S3 Table).
Extracellular staining of NK and T cells
For phenotypic analysis of NK cells, PBMC were stained with the following fluorochrome conju-
gated antibodies or isotype matched controls: CD3-Cy5.5/PerCP or CD3/Pe-Cy7, (eBioscience,
Hatfield, UK), CD56-PE Texas Red (Beckman Coulter, HighWycombe, UK), CD56-FITC,
CD16-APC Cy7, HLA-DR V500, CXCR3-Cy.5./PerCP, CD57-BV605, NKp46-V450, TRAIL-PE,
(BD Biosciences, Oxford, UK), TRAIL-BV421, CD62L-AF700, CXCR6-PE, CD69-APC,
CCR7-BV421, KLRG1-FITC, (Biolegend, London, UK), NKG2A-APC, NKG2C-Cy5.5/PerCP,
NKG2D-PE (R&D systems, Abingdon, UK), NKp30-APC, NKp44-PE (Miltenyi Biotec, Surrey,
UK), in the presence of fixable live/dead stain (Invitrogen, Paisley, Scotland). For phenotypic
analysis of T cells PBMC were stained with the fluorochrome conjugated antibodies or isotype
matched controls: CD3/Pe-Cy7, CD8-AF700, CD4-APC Cy7 (eBioscience, Hatfield, UK),
CD38-PE Texas Red, CD14-V500, CD19-V500 (Biolegend, London, UK). Flourescence minus-
one (FMOs) were used for gating purposes for all flourochromes; an example of the gating strat-
egy is shown in S1A Fig. Cells were acquired on a FACS LSRII multicolour flow cytometer (Beck-
ton Dickinson) and analysed using Flow Jo analysis software (Tree star, Ashland, OR, USA). In
addition to percentage, absolute numbers of NK cell subsets were calculated by multiplying their
percent by total lymphocyte count.
Intracellular staining and effector functions of NK cells
To assess proliferation and further characterisation of the differentiation of NK cells, PBMC
were permeabilised and stained with anti-Ki67-PE (eBioscience, Hatfield, UK), Granzyme-
B-FITC and Perforin-Cy5.5/PerCP (Biolegend, London, UK) directly ex-vivo. For intracellular
staining for IFNγ production; PBMC were incubated with rhIL12 and rhIL15 (10ng/ml) (R&D
systems, Abingdon, UK), for 19 hours at 37°C. 1mMmonensin (Sigma-Aldrich, Gillingham,
UK) was added for the final 3 hours. Cells were then stained with anti-CD3-Cy5.5/PerCP or
CD3/Pe-Cy7, CD16-APCy7, CD56-FITC, and subsequently fixed and permeabilised, followed
by intracellular staining for IFNγ-v450 (BD Biosciences, Oxford, UK). Dead cells were
excluded by fixable live dead stain.
For degranulation, PBMCs were incubated with K562 cells (5:1 E:T ratio) for 3 hours fol-
lowing overnight stimulation with a combination of 50ng/ml rhIL12 and rhIL18 (Miltenyi
Biotech). Anti-CD107a-PE mAb (BD Biociences, Oxford, UK) was added at the time of stimu-
lation with target-cells and monensin (1mM) added during the last 2 hours of incubation prior
to staining and acquisition.
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Virus-specific CD8 T cell analysis
Patients were tested for their HLA-A2 status and PBMC from HLA-A2+ patients were stimu-
lated with peptides representing HLA-A2-restricted HBV epitopes (HBVenv: FLLTRILTI,
WLSLLVPFV, LLVPFVQWFV, GLSPTVWLSV; HBVcore: FLPSDFFPSV; HBVpol: GLSRY-
VARL, KLHLYSHPI) or the CMV pp65-encoded NLVPMVATV epitope (Proimmune).
Virus-specific cells were identified by multicolour flow-cytometry (BD LSR II): surface staining
with CD3/Pe-Cy7, CD8-AF700, CD4-APC Cy7 (eBioscience, Hatfield, UK), CD38-PE Texas
Red, CD14-V500, CD19-V500 (Biolegend, London, UK) in the presence of fixable live/dead
stain (Invitrogen).
Statistical analysis
Significance was performed between paired samples; (pre-treatment, on PegIFNα therapy and
on sequential therapy), in addition to longitudinal analysis of samples using repeated Anova
measurements. P<0.05 was considered significant in all cases. (Prism version 5, GraphPad
Software Inc., San Diego, Calif.).
Supporting Information
S1 Fig. Impact of PegIFNα therapy and sequential NUC therapy on proliferative capacity
and activation of NK cells. (A) Gating strategy for identification of NK cells and markers (sin-
glets, total lymphocytes, live cells, CD3- CD56+ cells) using multicolour flow cytometry, gating
with FMO and mAb shown for CD62L as an example; all other markers analysed using the
same gating strategy. Cumulative longitudinal data demonstrating change in (B) Ki67+ and
(C) HLA-DR+ CD56bright and CD56dim NK cells over the course of PegIFNα therapy by per-
cent and absolute cell number (median ± 95%CI), (n = 18). Percent of (D) Ki67+ and (E)
HLA-DR+ CD56dim NK cells pre-treatment, the last sampling time-point of PegIFNα and at
viral suppression on sequential NUC therapy (significant increases marked with asterisks;
P<0.05;P<0.01;P<0.001, ns = not significant).
(PDF)
S2 Fig. Impact of PegIFNα therapy and sequential NUC therapy on C-type lectin receptor
expression. Cumulative longitudinal data demonstrating change in (A) NKG2D+ and (B)
NKG2A+ CD56bright and CD56dim NK cells over the course of PegIFNα therapy by percent
and absolute cell number (median ± 95%CI), (n = 18). Percent of (C) NKG2D+ and (D)
NKG2A+ CD56dim NK cells pre-treatment, the last sampling time-point of PegIFNα and at
viral suppression on sequential NUC therapy. Cumulative longitudinal data demonstrating
change in (E) NKG2C+ CD56bright and CD56dim NK cells over the course of PegIFNα therapy
by percent and absolute cell number (median ± 95%CI), (n = 18). Percent of (F) NKG2C+
CD56bright and (G) NKG2C+ CD56dim NK cells in 9 paired cross-sectional samples pre-treat-
ment, the last sampling time-point of PegIFNα and at viral suppression on sequential NUC
therapy with representative FACS plots at these time-points. (Significant increases marked
with asterisks; P<0.05;P<0.01;P<0.001, ns = not significant).
(PDF)
S3 Fig. Impact of PegIFNα therapy and sequential NUC therapy on NCR expression.
Cumulative longitudinal data demonstrating change in (A) NKp30+, (B) NKp44+ and (C)
NKp46+ CD56bright and CD56dim NK cells over the course of PegIFNα therapy by percent and
absolute cell number (median ± 95%CI), (n = 18). Percent of (D) NKp30+, (E) NKp44+ and
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(F) NKp46+ CD56dim NK cells pre-treatment, the last sampling time-point of PegIFNα and at
viral suppression on sequential NUC therapy (significant increases above baseline marked with
asterisks; P<0.05; P<0.01;P< .001, ns = not significant).
(PDF)
S4 Fig. Impact of PegIFNα therapy and sequential NUC therapy on the functional capacity
of NK cells. Cumulative longitudinal data demonstrating change in (A) TRAIL+, (B) CD107+
and (C) IFNγ+ CD56bright and CD56dim NK cells over the course of PegIFNα therapy by percent
and absolute cell number (median ± 95%CI), (n = 18). Percent of (D) TRAIL+, (E) CD107+ and
(F) IFNγ+ CD56dim NK cells pre-treatment, the last sampling time-point of PegIFNα and at
viral suppression on sequential NUC therapy (significant increases above baseline marked with
asterisks; P<0.05;P<0.01;P<0.001, ns = not significant).
(PDF)
S5 Fig. Comparison of markers of activation, migration, cytotoxicity and maturation dur-
ing sequential NUC therapy compared with de novo NUC therapy and PegIFNα only ther-
apy. Percentage of: (A) HLA-DR+, (B) NKG2C+ CD56bright NK cells, markers of migration; C)
CCR7+ and (D) CXCR6+ CD56bright and CD56dim NK cells, (E) Perforin+ and (F) Granzyme+
CD56bright and CD56dim NK cells and markers of maturation; (G) CD57+, (H) KLRG1+ and
(I) CD16+ CD56bright and CD56dim NK cells from patients in each treatment cohort (as in Fig
1). Sequential NUC therapy (Cohort 1; n = 14, red outline bars), compared with the cohorts of
patients treated with nucleos(t)ide analogues—de novo NUC therapy (Cohort 2; n = 12, green
outline bars), without previous PegIFNα exposure, and with PegIFNα alone with no further
therapy for 9 months (Cohort 3; n = 10, grey outline bars). Sampling time-point is at viral sup-
pression for patients in cohort 1 and 2. The end of treatment (EoT) PegIFNα sampling time-
point for cohort 1, is shown in the blue outline bars for comparison. Results are expressed as
mean ± SEM. Significant changes marked with asterisks, P<0.05;P<0.01; P<0.001,
ns = not significant.
(PDF)
S6 Fig. Impact of differing therapies on T cell numbers. Percentage of (A) CD8+ and (B)
CD4+ T cells. Patients from each cohort were tested for HLA-A2 status; positive patients (see
Supporting Tables) were tested for HBV-specific T cells, (C) Representative FACS plots and
summary data of HBV-specific CD8+ T cells, in the cohort of patients treated with sequential
NUC therapy (Cohort 1; n = 14, HLA-A2+; n = 5, red outline bars), compared with the cohorts
of patients treated with nucleos(t)ide analogues—de novo NUC therapy (Cohort 2; n = 12,
HLA-A2+; n = 5, green outline bars), without previous PegIFNα exposure, and with PegIFNα
alone with no further therapy for 9 months (Cohort 3; n = 10, HLA-A2+; n = 4, grey outline
bars). Sampling time-point is at viral suppression for patients in cohort 1 and 2. The end of
treatment (EoT) PegIFNα sampling time-point for cohort 1 is shown in the blue outline bars
for comparison (n = 14, HLA-A2+ n = 5). Results are expressed as mean ± SEM. Significant
changes marked with asterisks, P<0.05;P<0.01; P<0.001, ns = not significant.
(PDF)
S1 Table. Clinical parameters of sequential NUC therapy patients (Cohort 1). Numbers in
brackets under headings; ALT, HBV DNA & HBsAg are mean values.  denotes ALT, HBV
DNA & HBsAg at time of sequential NUC initiation.  denotes ALT, HBV DNA & HBsAg at
time of viral suppression. ^ denotes sustained HBsAg loss and § are patients sampled only at
selected time-points on sequential NUC therapy.
(PDF)
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S2 Table. Clinical parameters of de novo NUC therapy patients (Cohort 2).Numbers in
brackets under headings; age is the median value for the cohort, ALT, HBV DNA &HBsAg are
mean values.  denotes ALT, HBV DNA&HBsAg at time of de novo NUC initiation.  denotes
ALT, HBV DNA&HBsAg at time of viral suppression. ND–Test not done.
(PDF)
S3 Table. Clinical parameters of Peg-IFNα only therapy patients (Cohort 3). Numbers in
brackets under headings; age is the median value for the cohort, ALT, HBV DNA & HBsAg are
mean values.  denotes ALT, HBV DNA & HBsAg at baseline; prior to Peg-IFNα initiation.
 denotes ALT, HBV DNA & HBsAg at sampling time point (9–12 months post cessation of
Peg-IFNα). # denotes sustained HBeAg seroconversion & HBV DNA<2000 IU/ml 6-months
post cessation of Peg-IFNα, † indicates patients that refused sequential NUC therapy.
(PDF)
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